Skip to content 
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. more
| Time Frame | JNJ | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 2.6% | 1.75% | 1.05% |
| 1-Month Return | -4.31% | -3.02% | -2.74% |
| 3-Month Return | -6.56% | 1.93% | 4.56% |
| 6-Month Return | -1% | 11.24% | 20.31% |
| 1-Year Return | -7.17% | 6.02% | 24.48% |
| 3-Year Return | -2.5% | 19.75% | 26.81% |
| 5-Year Return | 21.36% | 76.04% | 88.12% |
| 10-Year Return | 93.68% | 186.26% | 224.44% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 82.06B | 82.58B | 93.78B | 94.94B | 85.15B | [{"date":"2019-12-31","value":86.43,"profit":true},{"date":"2020-12-31","value":86.98,"profit":true},{"date":"2021-12-31","value":98.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.69,"profit":true}] |
| Cost of Revenue | 27.56B | 28.43B | 29.86B | 31.09B | 26.74B | [{"date":"2019-12-31","value":88.64,"profit":true},{"date":"2020-12-31","value":91.44,"profit":true},{"date":"2021-12-31","value":96.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.01,"profit":true}] |
| Gross Profit | 54.50B | 54.16B | 63.92B | 63.85B | 58.41B | [{"date":"2019-12-31","value":85.27,"profit":true},{"date":"2020-12-31","value":84.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.9,"profit":true},{"date":"2023-12-31","value":91.38,"profit":true}] |
| Gross Margin | 66.42% | 65.58% | 68.16% | 67.26% | 68.60% | [{"date":"2019-12-31","value":96.82,"profit":true},{"date":"2020-12-31","value":95.6,"profit":true},{"date":"2021-12-31","value":99.37,"profit":true},{"date":"2022-12-31","value":98.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Expenses | 33.53B | 34.24B | 39.37B | 40.15B | 36.56B | [{"date":"2019-12-31","value":83.52,"profit":true},{"date":"2020-12-31","value":85.29,"profit":true},{"date":"2021-12-31","value":98.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.06,"profit":true}] |
| Operating Income | 21.01B | 19.82B | 24.42B | 23.92B | 21.85B | [{"date":"2019-12-31","value":86.04,"profit":true},{"date":"2020-12-31","value":81.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.95,"profit":true},{"date":"2023-12-31","value":89.5,"profit":true}] |
| Total Non-Operating Income/Expense | (3.64B) | (3.42B) | (1.77B) | (1.98B) | (6.30B) | [{"date":"2019-12-31","value":-364200000000,"profit":false},{"date":"2020-12-31","value":-341700000000,"profit":false},{"date":"2021-12-31","value":-177100000000,"profit":false},{"date":"2022-12-31","value":-197800000000,"profit":false},{"date":"2023-12-31","value":-630200000000,"profit":false}] |
| Pre-Tax Income | 17.33B | 16.50B | 22.78B | 21.73B | 15.06B | [{"date":"2019-12-31","value":76.08,"profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.39,"profit":true},{"date":"2023-12-31","value":66.13,"profit":true}] |
| Income Taxes | 2.21B | 1.78B | 1.90B | 3.78B | 1.74B | [{"date":"2019-12-31","value":58.38,"profit":true},{"date":"2020-12-31","value":47.12,"profit":true},{"date":"2021-12-31","value":50.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.88,"profit":true}] |
| Income After Taxes | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | [{"date":"2019-12-31","value":72.42,"profit":true},{"date":"2020-12-31","value":70.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":63.83,"profit":true}] |
| Income From Continuous Operations | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | [{"date":"2019-12-31","value":72.42,"profit":true},{"date":"2020-12-31","value":70.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":63.83,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 15.12B | 14.71B | 20.88B | 17.94B | 35.15B | [{"date":"2019-12-31","value":43.01,"profit":true},{"date":"2020-12-31","value":41.86,"profit":true},{"date":"2021-12-31","value":59.39,"profit":true},{"date":"2022-12-31","value":51.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 8.68 | 8.03 | 9.80 | 10.16 | 10.43 | [{"date":"2019-12-31","value":83.22,"profit":true},{"date":"2020-12-31","value":76.99,"profit":true},{"date":"2021-12-31","value":93.96,"profit":true},{"date":"2022-12-31","value":97.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| JNJ | |
|---|---|
| ROA (LTM) | 8.33% |
| ROE (LTM) | 18.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| JNJ | |
|---|---|
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 2.44 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| JNJ | |
|---|---|
| Trailing PE | 20.13 |
| Forward PE | 13.85 |
| P/S (TTM) | 4.17 |
| P/B | 5.17 |
| EV/R | 4.25 |
| EV/Ebitda | 15.52 |
| PEG | 0.10 |
In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks . These prospects result from industry titans’ forward-thinking initiatives and solid performance. The top seven of them are listed here. For example, the first company distinguishes itself by spending substantial research and development to gain a competitive advantage in several therapeutic areas. Similarly, the second company’s substantial expenditures on fiber networks and 5G put it in the lead in the telecom market. Its solid cash flow and well-thought-out client retention tactics highlight the third company’s stability and resilience. In the meantime, the fourth company’s calculated acquisitions in the cancer and cardiovascular fields show that it is acutely aware of the need to capitalize on high-growth markets. Furthermore, the fifth company’s innovative strides in pharmacy operations and digital expansion, the sixth company’s successful return to market share, and the seventh company’s dominance in distribution paint a vivid picture of diverse opportunities across multiple industries.
Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.
Not all stocks have succeeded in the bull market that began about 18 months ago. In the current market , a rising tide has not lifted all boats. In fact, there are some very notable names that are currently on the decline. Who would have predicted a year ago that names such as electric vehicle maker Tesla (NASDAQ: TSLA ) and consumer electronics giant Apple (NASDAQ: AAPL ) would be down by double digits and badly lagging the benchmark S&P 500 index? Yet this is the case as the competitive landscape and consumer trends have shifted. Once true blue stocks and reliable brands can no longer be trusted to deliver outsized gains to shareholders and surpass market returns. As such, investors are having to adjust their thinking and reevaluate their approach to stock picking. Here at InvestorPlace, we aim to help and offer the following warning. These three clue-chip stocks will have you seeing red. Avoid them at all costs. Johnson & Johnson Source: Raihana Asral / Shutterstock.com Pharmaceutical giant Johnson & Johnson’s (NYSE: JNJ ) stock has been a crushing disappointment for a long time.
Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and other interested parties Jetzt den vollständigen Artikel lesen
ArriVent BioPharma, Inc. appoints Kristine Peterson, a seasoned biopharmaceutical executive, to its Board of Directors. With over 30 years of industry experience, including leadership roles at major companies like Johnson & Johnson and Bristol-Myers Squibb, Peterson''s expertise will be important as ArriVent advances the development of firmonertinib for non-small cell lung cancer. Her track record of successful product launches and commercialization efforts makes her a valuable addition to the team, aiming to maximize the potential of ArriVent''s pipeline and deliver transformative medicines to cancer patients in need.
Dividend stocks have a proven record of stock market outperformance. For nearly 100 years, income-generating stocks on the S&P 500 have beaten non-payers. There has never been a decade when dividend stocks didn’t produce a positive return. And then we have the dividend royalty, companies that have raised their payouts the longest. These Dividend Kings have increased their dividends every year for 50 years or more without fail. Through wars, recessions and global pandemics, these businesses kept rewarding their investors for sticking by them. That doesn’t mean, however, their stocks will always go up. Economic factors and global events can temporarily slow business, causing investors to seek out faster growing stocks. But over time the Dividend Kings always rebound, explaining why they can still claim their thrones. The following are three royal dividend payers whose stocks are down 10% or more this year. You might want to consider buying these dividend stocks before they rebound once more.
In February, I recommended five one-month momentum plays to buy as Bitcoin ( BTC-USD ) prices surged. The world’s largest cryptocurrency is a surprisingly good gauge of bubbly investor sentiment, and our writers at InvestorPlace.com had found several strong candidates to ride the market higher. Over the following month, these picks would rocket 47%, on average. Even assets with relatively weak fundamentals will go up if investors are bullish enough. Ticker Name 18-Feb Price 18-Mar Price Change PLUG Plug Power $ 4.00 $3.30 -15.9% SOUN SoundHoundAI $3.80 $8.90 133.2% NVDA Nvidia $726.10 $878.40 21.0% ETH Ethereum $2,881.30 $3,518.40 22.1% SOL-USD Solana $112.20 $196 74.7% Average Return 47.0% However, market sentiment has since soured. Bitcoin has lost 18% of its value since peaking in mid-March, and many smaller cryptocurrencies have fallen even further. There are other signs of growing market fear. On Monday, the CBOE Volatility Index (VIX) surged from its previous Friday low of $15 to over $19.50. (Since 2001, any time the VIX has risen more than 25% in a trading day, the market would go on to underperform its long-term average by an annualized 7.4% over the following 30 days).
Johnson & Johnson and Kenvue Inc. were ordered to pay $45 million to the family of an Illinois woman who blamed the companies'' baby powders for giving her a fatal cancer
Johnson & Johnson and Kenvue Inc. were ordered to pay $45 million to the family of an Illinois woman who blamed the companies'' baby powders for giving her a fatal cancer
Johnson & Johnson (JNJ) share price today is $148.53
Yes, Indians can buy shares of Johnson & Johnson (JNJ) on Vested. To buy Johnson & Johnson from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JNJ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Johnson & Johnson (JNJ) via the Vested app. You can start investing in Johnson & Johnson (JNJ) with a minimum investment of $1.
You can invest in shares of Johnson & Johnson (JNJ) via Vested in three simple steps:
The 52-week high price of Johnson & Johnson (JNJ) is $173.31. The 52-week low price of Johnson & Johnson (JNJ) is $143.13.
The price-to-earnings (P/E) ratio of Johnson & Johnson (JNJ) is 10.83
The price-to-book (P/B) ratio of Johnson & Johnson (JNJ) is 5.17
The dividend yield of Johnson & Johnson (JNJ) is 3.32%
The market capitalization of Johnson & Johnson (JNJ) is $358.26B
The stock symbol (or ticker) of Johnson & Johnson is JNJ
Link copied 
